Cardiology Containment Medicine 
Scienmag
MARCH 3, 2021
Injecting hydrogels containing stem cell or exosome therapeutics directly into the pericardial cavity could be a less invasive, less costly, and more effective means of treating cardiac injury, according to new research from North Carolina State University and the University of North Carolina at Chapel Hill.
The Pharma Data
MARCH 31, 2023
About our longstanding commitment to heart failure Our goal is to reimagine medicine for HF patients. Entresto is a twice-a-day medicine that reduces the strain on the failing heart 4,5. Entresto contains the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan 4,5.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 20, 2021
Statistician: Dr. George Wells – Professor, School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa and Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute. Dr. Bennett is a board-certified cardiologist and board-eligible in critical care medicine.
The Pharma Data
DECEMBER 12, 2020
We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients.” ” Ludwig Hantson , Ph.D., Strategic rationale.
The Pharma Data
NOVEMBER 4, 2020
Food and Drug Administration and European Medicine Agency as a potential therapy for patients with AL amyloidosis. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.
The Pharma Data
NOVEMBER 19, 2020
15 in the New England Journal of Medicine. Each patient was given four bottles of statins and four bottles of placebos, each containing identical-looking tablets to be consumed in random order over eight months. He and his colleagues published their findings Nov. The study received no drug industry funding.
The Pharma Data
AUGUST 29, 2020
Presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, the analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran) from the Phase III trials.
Expert insights. Personalized for you.
73 
Let's personalize your content